

ACG Clinical Guideline: Ulcerative Colitis in Adults

American Journal of Gastroenterology

114, 384-413

DOI: [10.14309/ajg.0000000000000152](https://doi.org/10.14309/ajg.0000000000000152)

Citation Report

#	ARTICLE	IF	CITATIONS
1	<p></p>Patient and physician preferences for ulcerative colitis treatments in the United States</p>. Clinical and Experimental Gastroenterology, 2019, Volume 12, 263-278.	1.0	27
2	An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs, 2019, 7, 295-304.	0.5	1
3	The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2019, 17, 420-433.	0.3	6
4	The Clinical Accuracy of the BÂuml;HLMANN fCAL ELISA in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Multicenter Prospective Case“Control Study. Crohn's & Colitis 360, 2019, 1, .	0.5	2
5	PREVENTION OF INFLAMMATORY BOWEL DISEASE COMPLICATIONS AND RECURRENCE. Revista MÂdica ClÂnica Las Condes, 2019, 30, 339-343.	0.2	0
6	Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. Inflammatory Bowel Diseases, 2020, 26, 1225-1231.	0.9	30
7	Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence. Current Treatment Options in Gastroenterology, 2019, 17, 564-576.	0.3	23
8	Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. Inflammatory Intestinal Diseases, 2019, 4, 131-143.	0.8	6
9	Editorial: accelerated infliximab induction”it's time to settle the debate! Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1061-1062.	1.9	0
10	Maneuvering Clinical Pathways for Ulcerative Colitis. Current Gastroenterology Reports, 2019, 21, 52.	1.1	2
11	Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. Inflammatory Intestinal Diseases, 2019, 4, 115-122.	0.8	4
12	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 2019, 381, 1215-1226.	13.9	457
13	The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. Nutrients, 2019, 11, 1019.	1.7	140
14	706–Impact of Baseline Corticosteroid Therapy on Tofacitinib Induction Efficacy and Infection Risk in Patients With Ulcerative Colitis: Data From Global Clinical Trials. American Journal of Gastroenterology, 2019, 114, S415-S415.	0.2	5
15	705–Tofacitinib for the Treatment of Ulcerative Colitis: An Update on the Analysis of Malignancy Rates From the UC Clinical Program. American Journal of Gastroenterology, 2019, 114, S414-S415.	0.2	1
16	Inhibitors of the Janus Kinases. Journal of Clinical Gastroenterology, 2019, 53, 635-640.	1.1	5
17	IBD in the Elderly: Management Challenges and Therapeutic Considerations. Current Gastroenterology Reports, 2019, 21, 60.	1.1	24
18	The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2019, 17, 435-448.	0.3	2

#	ARTICLE	IF	CITATIONS
19	UEG Week 2019 Poster Presentations. United European Gastroenterology Journal, 2019, 7, 189-1030.	1.6	6
20	High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial. American Journal of Gastroenterology, 2019, 114, 1642-1648.	0.2	36
21	Histologic Remission in Ulcerative Colitis: Are We There Yet?. American Journal of Gastroenterology, 2019, 114, 713-715.	0.2	5
22	<p>Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data</p>. Drug Design, Development and Therapy, 2019, Volume 13, 4091-4105.	2.0	16
23	Inflammatory bowel disease during pregnancy. Current Opinion in Gastroenterology, 2019, 35, 281-287.	1.0	7
24	Clinical Implications of the CMV-Specific T-Cell Response and Local or Systemic CMV Viral Replication in Patients With Moderate to Severe Ulcerative Colitis. Open Forum Infectious Diseases, 2019, 6, ofz526.	0.4	3
25	Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis. ACG Case Reports Journal, 2019, 6, e00226.	0.2	12
26	Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. Inflammatory Bowel Diseases, 2020, 26, 941-948.	0.9	6
27	Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clinical Gastroenterology and Hepatology, 2020, 18, 987-988.e1.	2.4	4
28	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 363-378.	1.4	58
29	Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clinical and Translational Science, 2020, 13, 238-259.	1.5	12
30	Efficacy and safety of tofacitinib dose deéescalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary Pharmacology and Therapeutics, 2020, 51, 271-280.	1.9	65
31	Ulcerative Colitis: Current and Emerging Treatment Strategies. Journal of Clinical Medicine, 2020, 9, 94.	1.0	53
32	Increased risk of high-grade dysplasia and colorectal cancer in inflammatory bowel disease patients with recurrent low-grade dysplasia. Gastrointestinal Endoscopy, 2020, 91, 1334-1342.e1.	0.5	8
33	Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. Journal of Medical Economics, 2020, 23, 415-427.	1.0	11
34	Is there room for immunomodulators in ulcerative colitis?. Expert Opinion on Biological Therapy, 2020, 20, 379-390.	1.4	4
35	Is there a role for therapeutic sphingolipids in inflammatory bowel disease?. Expert Review of Gastroenterology and Hepatology, 2020, 14, 47-54.	1.4	6
36	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 2020, 382, 92-94.	13.9	6

#	ARTICLE	IF	CITATIONS
37	Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 34-40.	0.6	9
38	Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2510-2517.e5.	2.4	46
39	Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1261-1267.	2.4	22
40	Biotin Supplementation Ameliorates Murine Colitis by Preventing NF- κ B Activation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 557-567.	2.3	30
41	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 637-643.	1.9	37
42	Use of the Multiplex Diagnostic PCR Panel in Diarrheal Disease: Expert Guidance on the Interpretation of Results With a Focus on Travelers' Diarrhea. <i>American Journal of Gastroenterology</i> , 2020, 115, 1553-1555.	0.2	3
43	Treatment of Recurrent <i>Clostridioides difficile</i> Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 563-570.	1.6	9
44	Accuracy of Self-Reported Vaccination Status in a Cohort of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2935-2941.	1.1	22
45	Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Nutrition</i> , 2021, 60, 2293-2316.	1.8	40
46	Mesalamine in the Initial Therapy of Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 689-704.	1.0	9
47	Assessing Severity of Disease in Patients with Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 671-688.	1.0	49
48	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 105-115.e14.	2.4	31
49	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	2.4	32
50	Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1800-1813.e4.	2.4	70
51	Are Nutrition Interventions to Augment Treatment Plans the Most Personalized Approach to Inflammatory Bowel Disease Therapy?. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	0
52	Diet Recommendations for Hospitalized Patients With Inflammatory Bowel Disease: Better Options Than Nil Per Os. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	3
53	Exposure to Tofacitinib Not Related to Recurrence of Anal Premalignant Lesion: A Case Report. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e155-e156.	0.9	1
54	IBD considerations in spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093941.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Editorial: pancreatic cancer risk in inflammatory bowel diseasesâ€”it's all relative. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 550-551.	1.9	2
56	Inflammatory Bowel Disease â€” Non-biological treatment. <i>Pharmacological Research</i> , 2020, 160, 105075.	3.1	44
57	Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. <i>Current Gastroenterology Reports</i> , 2020, 22, 47.	1.1	8
58	A comparison of the efficacy and safety of complementary and alternative therapies for ulcerative colitis. <i>Medicine (United States)</i> , 2020, 99, e21219.	0.4	2
59	Can fecal calprotectin serve as a screen for necrotizing enterocolitis in infants?. <i>Clinical Biochemistry</i> , 2020, 84, 51-54.	0.8	3
60	Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. <i>Digestive Diseases and Sciences</i> , 2020, 66, 3985-3992.	1.1	1
61	A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares. <i>Digestive Diseases and Sciences</i> , 2020, 66, 3740-3752.	1.1	1
62	Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placebo controlled randomized trial. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 949-955.	2.0	15
63	Identification of Common Differentially Expressed Genes and Potential Therapeutic Targets in Ulcerative Colitis and Rheumatoid Arthritis. <i>Frontiers in Genetics</i> , 2020, 11, 572194.	1.1	14
64	Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3732-3745.	1.3	11
65	Solving the questions regarding 5-aminosalicylate formulation in the treatment of ulcerative colitis. <i>Journal of Gastroenterology</i> , 2020, 55, 1013-1022.	2.3	7
66	Review of the epidemiology and burden of ulcerative colitis in Latin America. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093173.	1.4	27
67	Are calprotectin and lactoferrin equivalent screening tests for inflammatory bowel disease?. <i>Clinica Chimica Acta</i> , 2020, 510, 191-195.	0.5	4
68	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohnâ€™s Disease. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 1028-1052.	0.7	56
69	Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5223.	1.8	10
70	Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2286.	1.0	7
71	Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3111-3115.	1.1	3
72	TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a Userâ€™s Guide: An Update. <i>Digestion</i> , 2020, 101, 16-26.	1.2	46

#	ARTICLE	IF	CITATIONS
73	Heading in the Right Dissection: Toward an Endoscopic Cancer Cure in a Patient with Long-Standing Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2818-2822.	1.1	0
74	Women's Health and Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 769-789.	1.0	9
75	Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis. <i>Medicine (United States)</i> , 2020, 99, e22894.	0.4	8
76	Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 655-669.	1.0	47
77	Nonbiologic Immune Suppression in Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 731-738.	1.0	1
78	Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form). <i>Gastroenterology Clinics of North America</i> , 2020, 49, 705-716.	1.0	10
79	The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1201-1209.	0.9	6
80	Biologic Therapy for Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 717-729.	1.0	21
81	Risk of Colon Cancer and Recommended Surveillance Strategies in Patients with Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 791-807.	1.0	16
82	Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 116-125.e5.	2.4	23
83	Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis. <i>Journal of Pharmacy Practice</i> , 2020, 34, 089719002095301.	0.5	8
84	Complexities of the Microbiome: Jaundice in Patient With Ulcerative Colitis. <i>Journal for Nurse Practitioners</i> , 2020, 16, e133-e136.	0.4	0
85	Ulcerative Colitis in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1205.	3.8	12
86	Efficacy and safety evaluation of acupoint embedding for patients with ulcerative colitis. <i>Medicine (United States)</i> , 2020, 99, e21812.	0.4	1
87	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 74.	18.1	678
88	Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 851-863.	1.1	7
89	Sporadic adenoma or ulcerative colitis associated neoplasia? The endoscopist's information has an impact on diagnosis and patient management. <i>Pathology Research and Practice</i> , 2020, 216, 153162.	1.0	2
90	Assessment of Vedolizumab Disease-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases. <i>Clinical Pharmacology in Drug Development</i> , 2020, 10, 734-747.	0.8	4

#	ARTICLE	IF	CITATIONS
91	Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2020, 27, 1620-1625.	0.9	7
92	Antibiotics for the induction and maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020, , .	1.5	1
93	The Therapeutic Effect of Shark Liver Oil in a Rat Model of Acetic Acid-Induced Ulcerative Colitis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-8.	0.5	2
94	Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. <i>Current Medical Research and Opinion</i> , 2020, 36, 1285-1294.	0.9	13
95	Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. <i>Annals of Pharmacotherapy</i> , 2020, 54, 1109-1143.	0.9	30
96	Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092077.	1.4	14
97	Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. <i>Current Opinion in Rheumatology</i> , 2020, 32, 371-379.	2.0	19
98	Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 786-794.	0.6	2
99	The treatment approach to inflammatory bowel disease in 2020. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 247-256.	1.0	8
100	Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 159, 1262-1275.e7.	0.6	101
101	The management of the hospitalized ulcerative colitis patient: the medical-surgical conundrum. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 265-276.	1.0	3
102	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 1457-1463.	0.9	40
103	The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. <i>Current Gastroenterology Reports</i> , 2020, 22, 36.	1.1	31
104	Chromoendoscopy in inflammatory bowel disease. , 2020, , 265-309.		0
105	The incidence of venous thromboembolism in children following colorectal resection for inflammatory bowel disease: A multi-center study. <i>Journal of Pediatric Surgery</i> , 2020, 55, 2387-2392.	0.8	6
106	Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools. <i>New England Journal of Medicine</i> , 2020, 382, 1042-1052.	13.9	1
107	Reappraising Risk Factors for Inflammatory Bowel Disease-associated Neoplasia: Implications for Colonoscopic Surveillance in IBD. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1172-1177.	0.6	10
108	Investigation of Potential Genetic Biomarkers and Molecular Mechanism of Ulcerative Colitis Utilizing Bioinformatics Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	22

#	ARTICLE	IF	CITATIONS
109	Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1202-1213.	0.6	57
110	Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000536.	3.9	17
111	Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. <i>Digestive and Liver Disease</i> , 2020, 52, 1259-1265.	0.4	7
112	Reorganization of the endoscopic activity of Cancer Institutes during phase II of the Covid-19 emergency. <i>Digestive and Liver Disease</i> , 2020, 52, 1346-1350.	0.4	0
113	Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. <i>American Journal of Gastroenterology</i> , 2020, 115, 1007-1018.	0.2	3
114	Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. <i>United European Gastroenterology Journal</i> , 2020, 8, 933-941.	1.6	18
115	Is tofacitinib a game-changing drug for ulcerative colitis?. <i>United European Gastroenterology Journal</i> , 2020, 8, 755-763.	1.6	12
116	No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 481-491.	1.9	10
117	Practice pattern variability in the management of acute severe colitis: a UK provider survey. <i>Frontline Gastroenterology</i> , 2020, 11, 272-279.	0.9	6
118	Histologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right?. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1730-1732.	0.9	1
119	Toxic Epidermal Necrolysis Because of Various Herpesviruses Infection After Accelerated Infliximab Induction in a Chinese Patient With Acute Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e38-e40.	0.9	1
120	Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1162-1171.	0.6	50
121	Cytomegalovirus infection is associated with worse outcomes in inflammatory bowel disease hospitalizations nationwide. <i>International Journal of Colorectal Disease</i> , 2020, 35, 897-903.	1.0	13
122	Modern surgery for ulcerative colitis. <i>Updates in Surgery</i> , 2020, 72, 325-333.	0.9	8
123	Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 1-11.	3.0	5
124	Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. <i>Current Medical Research and Opinion</i> , 2020, 36, 595-606.	0.9	22
125	Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. <i>PLoS ONE</i> , 2020, 15, e0227914.	1.1	31
126	Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update. <i>Digestion</i> , 2020, 101, 2-15.	1.2	53

#	ARTICLE	IF	CITATIONS
127	Anti-inflammation of Erianin in dextran sulphate sodium-induced ulcerative colitis mice model via collaborative regulation of TLR4 and STAT3. <i>Chemico-Biological Interactions</i> , 2020, 324, 109089.	1.7	21
128	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1345-1353.	0.6	9
129	A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e59-e61.	0.9	3
130	Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1413-1423.	0.6	22
131	<p>Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy</p>. <i>Core Evidence</i> , 2020, Volume 15, 7-20.	4.7	8
132	Smokers' reports on receiving a doctor's advice to quit smoking; receiving the advice is more prevalent among smokers with Crohn's Disease relative to smokers with Ulcerative Colitis. <i>Preventive Medicine Reports</i> , 2020, 18, 101091.	0.8	1
133	Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 27-35.	0.8	29
134	Steroid use and misuse: a key performance indicator in the management of IBD. <i>Frontline Gastroenterology</i> , 2021, 12, 207-213.	0.9	11
135	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 104-110.	2.4	60
136	Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 547-553.	1.1	8
137	Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics?. <i>Digestive Diseases and Sciences</i> , 2021, 66, 190-198.	1.1	8
138	Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 203-206.	0.9	27
139	UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2021, 12, 22-29.	0.9	11
140	Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. <i>Gut</i> , 2021, 70, 85-91.	6.1	171
141	Fully automated endoscopic disease activity assessment in ulcerative colitis. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 728-736.e1.	0.5	64
142	Dysplastic Progression to Adenocarcinoma is Equivalent in Ulcerative Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 24-34.	0.6	15
143	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 637-645.	1.4	47
144	Trends in Morbidity and Mortality Following Colectomy Among Patients with Ulcerative Colitis in the Biologic Era (2002-2013): A Study Using the National Inpatient Sample. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2032-2041.	1.1	9

#	ARTICLE	IF	CITATIONS
145	A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 115-127.e30.	0.6	48
146	Effect of IBD medications on COVID-19 outcomes: results from an international registry. <i>Gut</i> , 2021, 70, 725-732.	6.1	240
147	IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2021, 36, 383-393.	1.0	1
148	Exploring the Potential Mechanism of Guchang Zhixie Wan for Treating Ulcerative Colitis by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation as Well as Cell Experiments. <i>Chemistry and Biodiversity</i> , 2021, 18, e2000810.	1.0	13
149	Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 115-126.	1.4	11
150	Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 275-289.	1.4	40
151	Copaifera malmei Harms leaves infusion attenuates TNBS-ulcerative colitis through modulation of cytokines, oxidative stress and mucus in experimental rats. <i>Journal of Ethnopharmacology</i> , 2021, 267, 113499.	2.0	10
152	Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2021, 160, 677-689.	0.6	64
153	Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 779-786.	0.9	26
154	Finding a Needle in the Haystack? Defining the Role of Random Biopsies in IBD Dysplasia Surveillance. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 787-790.	0.9	0
155	90-Day Specific Readmission for <i>Clostridium difficile</i> Infection After Hospitalization With an Inflammatory Bowel Disease Flare: Outcomes and Risk Factors. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 530-537.	0.9	5
156	The Role of Narrowed Spectrum Technologies and Dye-based Endoscopy in Inflammatory Bowel Disease: New Advances and Opportunities. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2021, 23, 42-56.	0.4	1
157	Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	5
158	Histologic Activity and Steroid Use History are Risk Factors of Clinical Relapse in Ulcerative Colitis with Endoscopic Remission. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
159	Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. , 2021, , 1-23.		0
160	Magnetic resonance colonography with intestine-absorbable nanoparticle contrast agents in evaluation of colorectal inflammation. <i>European Radiology</i> , 2021, 31, 4615-4624.	2.3	3
161	Frailty in inflammatory bowel diseases: an emerging concept. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 1756284821110254.	1.4	22
162	Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 950-959.	0.6	42

#	ARTICLE	IF	CITATIONS
164	Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data. <i>Therapeutic Advances in Gastrointestinal Endoscopy</i> , 2021, 14, 263177452199062.	1.2	28
165	Efficacy of Multi Matrix System Mesalazine for the Induction of Remission in Patients with Ulcerative Colitis who Insufficiently Respond to other Mesalazine Formulations: A Japanese Single-center Study. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2021, 74, 357-363.	0.1	0
166	Predicting Outcome in Acute Severe Colitis – Controversies in Clinical Practice in 2021. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1211-1221.	0.6	17
167	The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review. <i>Medical Gas Research</i> , 2021, 11, 66.	1.2	6
168	A Phase 1 Study of KHK4083: A Single-blind, Randomized, Placebo-controlled Single-Ascending-Dose Study in Healthy Adults and an Open-label Multiple-Dose Study in Patients With Ulcerative Colitis. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 870-883.	0.8	4
169	Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review. <i>Biomolecules</i> , 2021, 11, 82.	1.8	36
170	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1120-1129.	0.6	59
171	Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110419.	1.1	6
172	Thermosensitive polymer hydrogel as a physical shield on colonic mucosa for colitis treatment. <i>Journal of Materials Chemistry B</i> , 2021, 9, 3874-3884.	2.9	27
173	Suppository treatment in ulcerative proctitis. <i>European Journal of Inflammation</i> , 2021, 19, 205873922110151.	0.2	0
174	Changing Paradigms in the Management of the Elderly IBD Patient. <i>Clinical Gastroenterology</i> , 2021, , 283-300.	0.0	0
175	Assessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	2
176	Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 229-240.	0.8	10
177	Colon Cancer Screening and Surveillance in the IBD Patient. <i>Clinical Gastroenterology</i> , 2021, , 245-263.	0.0	0
178	Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. <i>Clinical Gastroenterology</i> , 2021, , 61-88.	0.0	1
179	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	1.4	34
180	PET/computed tomography enterography. <i>Nuclear Medicine Communications</i> , 2021, 42, 694-698.	0.5	1
181	Evaluation of pharmacotherapy recommendations in guidelines for inflammatory bowel disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 599-609.	0.7	6

#	ARTICLE	IF	CITATIONS
182	Features of the gut microbiota in ulcerative colitis patients with depression. <i>Medicine (United States)</i> , 2021, 100, e24845.	0.4	19
183	Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study. <i>Intestinal Research</i> , 2022, 20, 64-71.	1.0	9
184	Role of Topical Tacrolimus in the Management of Proctitis, Perianal Manifestations in Crohn's Disease, and Chronic Pouchitis: A Systematic Review. <i>Journal of Investigative Medicine</i> , 2021, 69, 796-803.	0.7	3
185	Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine. <i>Frontiers in Pediatrics</i> , 2021, 9, 634739.	0.9	7
186	Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device. <i>Journal of Applied Laboratory Medicine</i> , The, 2021, 6, 931-941.	0.6	2
187	Cyclosporine modulates neutrophil functions via the SIRT6/HIF1 α glycolysis axis to alleviate severe ulcerative colitis. <i>Clinical and Translational Medicine</i> , 2021, 11, e334.	1.7	36
188	Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2610-2618.	0.9	15
189	Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies?. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000514.	1.5	4
190	Using Wearable Biosensors to Predict Length of Stay for Patients with IBD After Bowel Surgery. <i>Digestive Diseases and Sciences</i> , 2022, 67, 844-853.	1.1	8
192	The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015–2016. <i>Headache</i> , 2021, 61, 612-619.	1.8	9
193	Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 2010-2022.	0.9	4
194	Clinical features and treatment of inflammatory bowel disease in a low-incidence area. <i>Medicine (United States)</i> , 2021, 100, e25090.	0.4	9
195	Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 591-601.e8.	2.4	36
196	Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. <i>Gut and Liver</i> , 2021, 15, 232-242.	1.4	13
197	Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affairs Healthcare System. <i>Gut</i> , 2021, 70, 1657-1664.	6.1	42
198	Endoscopy in Small Bowel Crohn's Disease. , 0, , .		0
199	Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. <i>BMC Gastroenterology</i> , 2021, 21, 121.	0.8	0
200	Dietary Gluten Intake Is Not Associated With Risk of Inflammatory Bowel Disease in US Adults Without Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 303-313.e6.	2.4	6

#	ARTICLE	IF	CITATIONS
201	Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines?. <i>Gastroenterology Report</i> , 2021, 9, 408-417.	0.6	1
202	Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 344-350.	1.0	5
203	Possible Earlier Diagnosis of Ulcerative Colitis-Associated Neoplasia: A Retrospective Analysis of Interval Cases during Surveillance. <i>Journal of Clinical Medicine</i> , 2021, 10, 1927.	1.0	3
204	Association Between Inflammatory Bowel Disease and Dementia: A Retrospective Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1471-1478.	1.2	26
205	Identification of key genes and biological processes contributing to colitis associated dysplasia in ulcerative colitis. <i>PeerJ</i> , 2021, 9, e11321.	0.9	6
206	Vasculitis leucocitoclásticas como manifestación extraintestinal dermatológica rara de la enfermedad inflamatoria intestinal asociada con Clostridium: reporte de un caso. <i>Revista Colombiana De Gastroenterología</i> , 2021, 36, 12-18.	0.1	1
207	Pathologist, Meet Picasso! Virtual Chromoendoscopy for Detecting Histologic Remission in Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 1469-1472.	0.6	4
208	Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 2586-2598.	1.3	13
209	PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization. <i>Frontiers in Pharmacology</i> , 2021, 12, 643215.	1.6	5
210	Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2021, 160, 1584-1598.	0.6	113
211	Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 806-811.	0.6	1
212	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 489-526.	2.3	202
213	Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD. <i>Crohn's & Colitis 360</i> , 2021, 3, .	0.5	3
214	A new approach to predict ulcerative colitis activity through standard clinical biological parameters using a robust neural network model. <i>Neural Computing and Applications</i> , 2021, 33, 14133-14146.	3.2	3
215	The Fate of Unifocal Versus Multifocal Low-Grade Dysplasia at the Time of Colonoscopy in Patients with Inflammatory Bowel Disease. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, 1364-1373.	0.7	3
216	Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. <i>World Journal of Gastroenterology</i> , 2021, 27, 2521-2530.	1.4	8
217	Rectal Cancer Incidence is Low Following Rectal Diversion or Subtotal Colectomy for IBD: Results of a Population-based Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1787-1798.	0.6	5
218	Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 553-559.	0.9	9

#	ARTICLE	IF	CITATIONS
219	A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2762-2768.	1.4	3
220	Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis. <i>ACG Case Reports Journal</i> , 2021, 8, e00604.	0.2	17
221	Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty. <i>Digestive Diseases and Sciences</i> , 2022, 67, 622-628.	1.1	19
222	Polydatin has anti-inflammatory and antioxidant effects in LPS-induced macrophages and improves DSS-induced mice colitis. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 959-970.	1.3	27
223	Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. <i>Translational Research</i> , 2021, , .	2.2	0
224	5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness?. <i>American Journal of Gastroenterology</i> , 2021, 116, 1958-1959.	0.2	0
225	Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN40943, a Gastrointestinal-Restricted Oral Peptide Antagonist of IL-17 , in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1263-1278.	0.8	9
226	Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis. <i>Advances in Therapy</i> , 2021, 38, 4115-4129.	1.3	1
227	The long-term incidence of dysplasia and colorectal cancer in a Crohn's colitis population-based cohort. <i>Colorectal Disease</i> , 2021, 23, 2399-2406.	0.7	4
228	Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines. <i>International Journal of Clinical Practice</i> , 2021, 75, e14365.	0.8	2
229	Single-stage restorative proctocolectomy for ulcerative colitis in pediatric patients: a safe alternative. <i>Pediatric Surgery International</i> , 2021, 37, 1453-1459.	0.6	2
230	Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2324-2332.e6.	2.4	28
231	Endoscopic submucosal dissection is safe and feasible, allowing for ongoing surveillance and organ preservation in patients with inflammatory bowel disease. <i>Colorectal Disease</i> , 2021, 23, 2100-2107.	0.7	10
232	Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2022-2030.	0.6	28
233	Predicting Colorectal Cancer Occurrence in IBD. <i>Cancers</i> , 2021, 13, 2908.	1.7	26
234	To Trap a Pathogen: Neutrophil Extracellular Traps and Their Role in Mucosal Epithelial and Skin Diseases. <i>Cells</i> , 2021, 10, 1469.	1.8	16
235	De Novo Inflammatory Bowel Disease Rarely Occurs During Posttransplant Immunosuppression. <i>American Journal of Clinical Pathology</i> , 2021, 156, 1113-1120.	0.4	0
236	Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	2

#	ARTICLE	IF	CITATIONS
237	Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	0
238	Response to Tetangco and Hanauer. <i>American Journal of Gastroenterology</i> , 2021, 116, 1959-1960.	0.2	0
239	Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	6
240	Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1170-1179.e10.	2.4	5
241	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre cribado de displasia en pacientes con enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 435-447.	0.2	4
242	Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Tj ETQq1 1 0.784314 rgBT /Over inflammatory bowel disease patients. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021, 44, 435-447.	0.0	2
243	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021, 53, 1571-1579.	0.4	3
244	Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021, 160, 2340-2353.	0.6	93
245	Overuse of Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease Compared to Non-IBD Patients on Biologic Therapy. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	2
246	Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1588-1597.e3.	2.4	12
247	Practice pattern variability among gastroenterologists in colorectal cancer surveillance and management of colorectal dysplasia in inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2021, 22, 463-472.	0.7	1
248	Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 1819-1821.	0.2	0
249	Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. <i>Gastroenterology</i> , 2021, 161, 47-65.	0.6	86
250	Artificial Sweeteners and Whole-Food Science: Could Mice Help Clinicians Make Diet Recommendations for IBD Patients?. <i>Gastroenterology</i> , 2021, 161, 8-14.	0.6	4
251	Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1174-1181.	1.0	9
252	An Unusual Cause of Large Bowel Obstruction in a Patient With Ulcerative Colitis. <i>ACG Case Reports Journal</i> , 2021, 8, e00638.	0.2	1
253	Venous Thromboembolism Among Patients With Inflammatory Bowel Diseases is Not Related to Increased Thrombophilia. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	1
254	Computed tomography enterocolonography in assessment of degree of ulcerative colitis activity. <i>International Journal of Clinical Practice</i> , 2021, 75, e14626.	0.8	3

#	ARTICLE	IF	CITATIONS
255	Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 745-754.	0.9	2
256	Calprotectin in viral systemic infections—COVID-19 versus hepatitis C virus. <i>Clinical and Experimental Medicine</i> , 2022, 22, 311-317.	1.9	2
257	State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation. <i>Clinical and Translational Imaging</i> , 2021, 9, 299-339.	1.1	70
258	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 783-804.	0.7	41
259	Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1850-1857.	1.1	3
260	Treatment outcomes of endoscopic submucosal dissection and surgery for colorectal neoplasms in patients with ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2021, 9, 964-972.	1.6	16
262	Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease. <i>Journal of Clinical Psychology in Medical Settings</i> , 2022, 29, 596-607.	0.8	12
263	Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center. <i>Crohn's & Colitis 360</i> , 2021, 3, .	0.5	1
264	Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	0
265	First or Second Biologic in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, 740-746.	1.1	0
266	miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis. <i>Frontiers in Pharmacology</i> , 2021, 12, 707776.	1.6	24
267	Individualized selection of biological agents in treatment of inflammatory bowel disease. <i>World Chinese Journal of Digestology</i> , 2021, 29, 893-900.	0.0	0
268	The importance of sarcopenia as a prognostic predictor of the clinical course in acute severe ulcerative colitis patients. <i>Digestive and Liver Disease</i> , 2021, 53, 965-971.	0.4	14
269	Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. <i>Cell Host and Microbe</i> , 2021, 29, 1294-1304.e4.	5.1	85
270	Comparison of inflammatory bowel disease relapse after top-down or step-up therapy: a population-based cohort study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2227-2235.	1.0	0
271	Comparison of Next-Generation Assays for Fecal Calprotectin vs the PhiCal Assay. <i>American Journal of Clinical Pathology</i> , 2022, 157, 252-256.	0.4	5
272	Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNF± in inflammatory bowel disease. <i>BMC Gastroenterology</i> , 2021, 21, 312.	0.8	10
273	The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1175-1181.	0.6	8

#	ARTICLE	IF	CITATIONS
274	Early Change in Fecal Calprotectin Predicts One-Year Outcome in Children Newly Diagnosed With Ulcerative Colitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 74, 72-78.	0.9	6
275	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 27-38.	0.6	66
276	A Multidisciplinary Approach to Rectal Cancer Treatment in Ulcerative Colitis Results in High Rate of Restorative Minimally Invasive Surgery. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 244-250.	0.6	1
277	Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1046-1055.	0.5	0
278	Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease. <i>Artificial Intelligence in Gastroenterology</i> , 2021, 2, 111-123.	0.2	1
279	Lentian-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 702173.	2.0	16
280	Current and future status of JAK inhibitors. <i>Lancet</i> , The, 2021, 398, 803-816.	6.3	117
281	Beyond the SCENIC route: updates in chromoendoscopy and dysplasia screening in patients with inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 30-37.	0.5	17
282	Management of Dysplasia in Ulcerative Colitis. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2021, 31, 855-860.	0.5	0
283	Interference With the AMPK/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofilling for the Management of Ulcerative Colitis. <i>Frontiers in Pharmacology</i> , 2021, 12, 719984.	1.6	34
284	Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 434-446.	0.9	14
285	Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2021, 53, 1171-1177.	0.4	6
286	Integrative analysis of ferroptosis-related genes in ulcerative colitis. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110429.	0.4	18
287	Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1299-1305.e5.	2.4	21
288	Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 167-175.	0.9	5
290	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2021, 385, 1280-1291.	13.9	243
291	5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 28-35.	0.8	7
292	Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease – What the Clinician Needs to Know. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 460-471.	0.6	5

#	ARTICLE	IF	CITATIONS
293	Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. <i>Pharmaceuticals</i> , 2021, 14, 922.	1.7	4
294	Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 50-58.	0.8	24
295	Computational drug repositioning of atorvastatin for ulcerative colitis. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 2325-2335.	2.2	10
296	Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2021, 37, 1891-1900.	0.9	10
297	Highly Multiplexed Image Analysis of Intestinal Tissue Sections in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021, 161, 1940-1952.	0.6	18
298	AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. <i>Gastroenterology</i> , 2021, 161, 1043-1051.e4.	0.6	102
299	Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. <i>European Journal of Internal Medicine</i> , 2021, 93, 35-41.	1.0	15
300	Ileostomy or ileal pouch-anal anastomosis for ulcerative colitis: patient participation and decisional needs. <i>BMC Gastroenterology</i> , 2021, 21, 347.	0.8	4
301	Effectiveness and Safety of Tofacitinib for Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e323-e333.	1.1	14
302	Motion-based camera localization system in colonoscopy videos. <i>Medical Image Analysis</i> , 2021, 73, 102180.	7.0	11
303	Soluble ligands as drug targets for treatment of inflammatory bowel disease. , 2021, 226, 107859.		10
304	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). <i>Gastroenterology</i> , 2021, 161, 1156-1167.e3.	0.6	21
305	Xianglian Pill Suppresses Inflammation and Protects Intestinal Epithelial Barrier by Promoting Autophagy in DSS Induced Ulcerative Colitis Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 594847.	1.6	16
306	Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. <i>Annals of Gastroenterology</i> , 2021, 34, 612-624.	0.4	1
307	Integrated Traditional Chinese and Western medicine for ulcerative colitis with diabetes. <i>Medicine (United States)</i> , 2021, 100, e24444.	0.4	3
308	Advances in Our Understanding of the Pathogenesis of Inflammatory Bowel Disease. <i>Clinical Gastroenterology</i> , 2021, , 1-23.	0.0	0
309	The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 695-707.	0.6	14
310	The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110233.	1.4	13

#	ARTICLE	IF	CITATIONS
311	Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. <i>Trials</i> , 2021, 22, 55.	0.7	1
312	Vedolizumab in Inflammatory Bowel Disease: West versus East. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 1-17.	0.8	1
313	Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 77, 12-21.	0.2	8
314	The rectal mucosal but not fecal microbiota detects subclinical ulcerative colitis. <i>Gut Microbes</i> , 2021, 13, 1-10.	4.3	4
315	International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPs Survey. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1942-1953.	0.9	30
316	Interventions for treating iron deficiency anaemia in inflammatory bowel disease. <i>The Cochrane Library</i> , 2021, 2021, CD013529.	1.5	12
317	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 581-594.	1.4	26
318	Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADE. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 1-57.	0.2	24
319	Crohn's Disease Is Associated With Activation of Circulating Innate Lymphoid Cells. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1128-1138.	0.9	18
320	Moderate to severe Endoscopic Inflammation is Frequent After Clinical Remission in Pediatric Ulcerative Colitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 569-573.	0.9	3
321	Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 220-233.	1.9	13
322	The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. <i>Gut</i> , 2021, 70, 2076-2084.	6.1	15
323	Immunosuppression and Malignant Neoplasms: Risk-Benefit Assessment in Patients with Inflammatory Bowel Disease. <i>American Journal of Case Reports</i> , 2020, 21, e920949.	0.3	3
324	Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2021, 116, 125-133.	0.2	10
325	Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert's opinion. <i>Sovremennaya Revmatologiya</i> , 2020, 14, 7-18.	0.1	3
326	Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review. <i>Journal of Medical Internet Research</i> , 2019, 21, e14630.	2.1	62
327	Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study. <i>JMIR Medical Informatics</i> , 2020, 8, e15124.	1.3	7
328	The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review. <i>Nutrients</i> , 2021, 13, 135.	1.7	65

#	ARTICLE	IF	CITATIONS
329	Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. <i>World Journal of Gastroenterology</i> , 2019, 25, 4148-4157.	1.4	109
330	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. <i>World Journal of Gastroenterology</i> , 2020, 26, 6710-6769.	1.4	12
331	>Clostridium butyricum protects intestinal barrier function via upregulation of tight junction proteins and activation of the Akt/mTOR signaling pathway in a mouse model of dextran sodium sulfateâ€induced colitis. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	21
332	Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 210.	0.5	7
333	Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2020, 11, 104-113.	0.5	26
334	2019 Expert opinion on biological treatment use in inflammatory bowel disease management. <i>Turkish Journal of Gastroenterology</i> , 2020, 30, S913-S946.	0.4	3
335	Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. <i>Intestinal Research</i> , 2021, 19, 419-429.	1.0	13
336	Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI). <i>Intestinal Research</i> , 2021, 19, 386-397.	1.0	16
337	Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis. <i>PeerJ</i> , 2020, 8, e9537.	0.9	10
338	Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Journal of Medical Internet Research</i> , 2022, 24, e28978.	2.1	19
339	Exploring the Potential Mechanism of Xiaokui Jiedu Decoction for Ulcerative Colitis Based on Network Pharmacology and Molecular Docking. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-11.	1.1	9
340	Faecal Calprotectin from Ileostomy Output Is Sensitive and Specific for the Prediction of Small Bowel Inflammation in Patients with Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 601-605.	0.6	3
341	Adherence to treatment in patients with inflammatory bowel disease. <i>Bulletin of Siberian Medicine</i> , 2021, 20, 120-128.	0.1	0
343	Overexpression of circAtp9b in ulcerative colitis is induced by lipopolysaccharides and upregulates PTEN to promote the apoptosis of colonic epithelial cells. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1404.	0.8	6
346	Colonic Conditions: Ulcerative Colitis. , 2020, , 405-416.		0
347	Single-Nucleotide Polymorphisms in Inflammatory Bowel Disease. , 0, , .		0
348	MHC Class I related chain A (MICA), Human Leukocyte Antigen (HLA)-DRB1, HLA-DQB1 genotypes in Turkish patients with ulcerative colitis. <i>Turkish Journal of Biochemistry</i> , 2020, 45, 587-592.	0.3	0
349	Recurrent Urinary Tract Infection in a Patient With Asymptomatic Crohn's Disease. <i>Cureus</i> , 2020, 12, e9962.	0.2	0

#	ARTICLE	IF	CITATIONS
350	Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. <i>Gastroenterology</i> , 2022, 162, 715-730.e3.	0.6	193
351	Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1592-1600.	0.5	3
352	Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease. <i>Hospital Pharmacy</i> , 2022, 57, 001857872098543.	0.4	0
353	Enfermedad inflamatoria intestinal durante el embarazo. <i>Revista Medica Sinergia</i> , 2020, 5, e614.	0.0	0
354	Thrombosis in IBD in the Era of JAK Inhibition. <i>Current Drug Targets</i> , 2020, 22, 126-136.	1.0	10
355	Colitis ulcerativa para no gastroenterólogos. <i>CES Medicina</i> , 2020, 34, 188-197.	0.1	0
356	Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts' opinion. <i>Almanah Kliničeskoj Mediciny</i> , 2020, 48, 422-436.	0.2	6
357	İnflamatuvar Bağırsak Hastalıkları Olan Bireylerde İlaç Uyumunu ve Yaşam Kalitesini Etkileyen Faktörlerin İncelenmesi. <i>Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri Ve Araştırmalar Dergisi</i> , 0, , .	0.6	0
358	ENDOSCOPIC DIAGNOSIS OF DYSPLASIA IN PATIENTS WITH LONGSTANDING ULCERATIVE COLITIS. <i>Koloproktologia</i> , 2020, 19, 37-50.	0.1	0
360	Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. , 2022, , 485-507.		0
361	Validation of a claims-based algorithm to identify cases of ulcerative colitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	4
362	<p>A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1059-1072.	1.5	3
363	Chapter 20: Prebiotics and Probiotics. , 2020, , .		0
364	Guía para el manejo de colitis ulcerativa en población adulta (actualización). <i>Revista Colombiana De Gastroenterología</i> , 2020, 35, 2-62.	0.1	4
365	Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis. <i>Medical Hypotheses</i> , 2020, 144, 110211.	0.8	1
367	Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 656-665.	0.2	15
368	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 265-272.	1.9	3
369	Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2020, 16, 449-457.	0.2	1

#	ARTICLE	IF	CITATIONS
370	Endoscopic Management of Complex Lesions in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2021, 17, 121-127.	0.2	0
371	A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , 2021, 17, 59-66.	0.2	0
372	The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice. <i>Gastroenterology and Hepatology</i> , 2021, 17, 3-13.	0.2	1
373	Highlights From the 2020 Virtual Advances in Inflammatory Bowel Diseases Conference: Commentary. <i>Gastroenterology and Hepatology</i> , 2021, 17, 15-18.	0.2	0
376	Efficacy and Safety of Melatonin as an Adjunctive Therapy on Clinical, Biochemical, and Quality of Life in Patients with Ulcerative Colitis. <i>Iranian Journal of Pharmaceutical Research</i> , 2021, 20, 197-205.	0.3	2
377	JAK-STAT Pathway Regulation of Intestinal Permeability: Pathogenic Roles and Therapeutic Opportunities in Inflammatory Bowel Disease. <i>Pharmaceuticals</i> , 2021, 14, .	1.7	2
378	CANCER PREVENTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Practical Gastroenterology</i> , 2021, 45, 12-28.	4.0	0
379	Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. <i>Gut Microbes</i> , 2021, 13, 1987779.	4.3	70
380	Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 342.	0.5	2
381	IBD Diagnosis and Evaluation. , 2022, , 751-764.		0
382	Association Between Inflammatory Bowel Disease and Dementia: A Longitudinal Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1520-1526.	0.9	15
383	Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis. <i>ACG Case Reports Journal</i> , 2021, 8, e00678.	0.2	6
384	Colorectal Dysplasia and Cancer Surveillance in Ulcerative Colitis. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 86.	1.0	3
385	Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5551.	1.0	9
386	Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. <i>Rheumatology and Therapy</i> , 2022, 9, 49-71.	1.1	3
387	In Vivo Healthy Benefits of Galacto-Oligosaccharides from <i>Lupinus albus</i> (LA-GOS) in Butyrate Production through Intestinal Microbiota. <i>Biomolecules</i> , 2021, 11, 1658.	1.8	13
388	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. <i>Journal of Clinical Medicine</i> , 2021, 10, 5642.	1.0	4
389	Medical Management of Ulcerative Colitis. , 2022, , 765-779.		0

#	ARTICLE	IF	CITATIONS
390	Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 186-198.	0.8	2
392	Management of Hospitalized Patients with Inflammatory Bowel Disease and CMV Infection or Clostridium Difficile Infection. , 2022, , 161-180.		2
393	Proteomic analysis of lysine acetylation reveals that metabolic enzymes and heat shock proteins may be potential targets for DSS-induced mice colitis. <i>International Immunopharmacology</i> , 2021, 101, 108336.	1.7	4
394	Quality of Care in the Management of Hospitalized Patients with Inflammatory Bowel Disease. , 2022, , 211-223.		0
395	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 464-478.	1.9	73
396	Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis. <i>Frontiers in Pharmacology</i> , 2021, 12, 769718.	1.6	6
397	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110599.	1.4	16
398	Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110547.	1.4	4
399	Metabolomics facilitate the personalized management in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110644.	1.4	9
400	AJM300 (Carotegrast Methyl), an Oral Antagonist of $\alpha 4$ -Integrin, as Induction Therapy for Patients with Moderately Active Ulcerative Colitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
401	Chinese consensus on prevention of colorectal neoplasia (2021, <sc>S</sc>hanghai). <i>Journal of Digestive Diseases</i> , 2022, 23, 58-90.	0.7	7
402	Cholinergic immunomodulation in inflammatory bowel diseases. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 19, 100401.	1.3	7
403	Infliximab as Rescue Therapy for Hospitalized Patients With Crohn's Disease Failing Intravenous Corticosteroids. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.5	0
404	Comparative characteristics of chronic colitis experimental models reproduced in vivo. <i>Medicina S¹ogodn¹ Zavtra</i> , 2022, 91, .	0.0	0
405	JAK-STAT Pathway Regulation of Intestinal Permeability: Pathogenic Roles and Therapeutic Opportunities in Inflammatory Bowel Disease. <i>Pharmaceuticals</i> , 2021, 14, 840.	1.7	15
406	Time to Flexible Sigmoidoscopy or Colonoscopy in Patients Admitted With Ulcerative Colitis Has Decreased From 2012 to 2018. <i>Crohn's & Colitis 360</i> , 2021, 3, .	0.5	0
407	Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2021, 50, 659-665.	0.1	0
408	Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1168-1176.	0.6	6

#	ARTICLE	IF	CITATIONS
409	PET Imaging of System \times_{C} in Immune Cells for Assessment of Disease Activity in Mice and Patients with Inflammatory Bowel Disease. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1586-1591.	2.8	5
410	Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons. <i>Clinics in Colon and Rectal Surgery</i> , 2022, 35, 066-071.	0.5	1
411	Perioperative management of biologic agents in ulcerative colitis. <i>Seminars in Colon and Rectal Surgery</i> , 2022, , 100866.	0.2	0
412	Advanced endoscopy for the management of inflammatory digestive diseases: Review of the Japan Gastroenterological Endoscopy Society core session. <i>Digestive Endoscopy</i> , 2022, 34, 729-735.	1.3	2
413	LCN2 as a Potential Diagnostic Biomarker for Ulcerative Colitis-Associated Carcinogenesis Related to Disease Duration. <i>Frontiers in Oncology</i> , 2021, 11, 793760.	1.3	8
414	High Degree of Practice Variability in Colonic Dysplasia Surveillance for Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1289-1292.	0.9	2
415	Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2358-2365.e11.	2.4	18
416	The Impact of Ulcerative Colitis on Colorectal Cancer Prognosis: The Jury is Still Out. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	1
418	Medical treatment of ulcerative colitis. <i>Seminars in Colon and Rectal Surgery</i> , 2022, 33, 100863.	0.2	2
419	Infliximab-Associated Xanthogranulomatous Pyelonephritis: A Rare Complication. <i>Cureus</i> , 2022, 14, e21051.	0.2	1
420	Cytomegalovirus in ulcerative colitis: an evidence-based approach to diagnosis and treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, , 1-12.	1.4	8
421	Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications. <i>Nutrients</i> , 2022, 14, 269.	1.7	39
422	Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. <i>Clinics in Colon and Rectal Surgery</i> , 2022, 35, 032-043.	0.5	1
423	Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question. <i>Journal of Clinical Medicine</i> , 2022, 11, 509.	1.0	1
424	Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change?. <i>European Medical Journal Innovations</i> , 0, , 40-49.	2.0	5
425	Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2347-2357.e14.	2.4	4
426	Health economic analyses of secondary vaccine effects: a systematic review and policy insights. <i>Expert Review of Vaccines</i> , 2022, 21, 297-312.	2.0	3
427	SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis. <i>Medicine (United States)</i> , 2022, 101, e28722.	0.4	3

#	ARTICLE	IF	CITATIONS
428	A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1549-1554.	0.9	10
429	Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021. <i>World Journal of Gastroenterology</i> , 2022, 28, 502-516.	1.4	8
430	Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis. <i>Journal of Ethnopharmacology</i> , 2022, 289, 115041.	2.0	7
431	Viral Enteric Infections in Acute Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1335-1339.	0.6	1
432	Pulsatilla decoction alleviates colitis by enhancing autophagy and regulating PI3K/Akt/mTORC1 signaling pathway. <i>Molecular Medicine Reports</i> , 2022, 25, .	1.1	10
433	Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3151-3172.	2.9	7
434	The Clinical Significance of Eosinophils in Ulcerative Colitis: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1321-1334.	0.6	4
435	Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. <i>Crohn's & Colitis 360</i> , 2022, 4, otac002.	0.5	28
436	How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 829.	1.0	9
437	Molecular mechanism of the TGFβ ² /Smad7 signaling pathway in ulcerative colitis. <i>Molecular Medicine Reports</i> , 2022, 25, .	1.1	4
438	Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis. <i>Gut and Liver</i> , 2022, 16, 736-745.	1.4	3
439	Oral Delivery of Pterostilbene by L-Arginine-Mediated "Nano-Bomb" Carrier for the Treatment of Ulcerative Colitis. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 603-616.	3.3	19
440	Network Pharmacology and Molecular Docking Analysis on Molecular Mechanism of Qingzi Zhitong Decoction in the Treatment of Ulcerative Colitis. <i>Frontiers in Pharmacology</i> , 2022, 13, 727608.	1.6	10
441	Endoscopic retrograde appendicitis therapy versus laparoscopic appendectomy versus open appendectomy for acute appendicitis: a pilot study. <i>BMC Gastroenterology</i> , 2022, 22, 63.	0.8	13
442	Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?. <i>Intestinal Research</i> , 2022, 20, 297-302.	1.0	4
443	Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget. <i>World Journal of Gastrointestinal Endoscopy</i> , 2022, 14, 85-95.	0.4	3
447	Aloe vera gel attenuates acetic acid-induced ulcerative colitis in adult male Wistar rats. <i>Toxicology Reports</i> , 2022, 9, 640-646.	1.6	5
448	Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis. <i>BMC Gastroenterology</i> , 2022, 22, 83.	0.8	1

#	ARTICLE	IF	CITATIONS
450	Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1402-1413.	1.9	9
452	Gegen Qinlian Decoction Alleviates Experimental Colitis and Concurrent Lung Inflammation by Inhibiting the Recruitment of Inflammatory Myeloid Cells and Restoring Microbial Balance. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1273-1291.	1.6	10
453	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. <i>Gastroenterology</i> , 2022, 162, 1891-1910.	0.6	28
454	The Burden of Vaccine-preventable Diseases in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 798-804.	1.1	9
455	Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report. <i>Annals of Medicine and Surgery</i> , 2022, 75, 103456.	0.5	1
456	Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. <i>BMC Gastroenterology</i> , 2022, 22, 92.	0.8	12
457	Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1192-1201.	1.9	14
458	AJM300 (carotegrast methyl), an oral antagonist of $\alpha 4$ -integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 648-657.	3.7	38
459	Evaluation of antibiotic appropriateness at an outpatient oncology centre. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 874-884.	0.5	1
460	Características de la enfermedad inflamatoria intestinal con respecto a otros centros nacionales de Colombia. <i>Revista Colombiana De Gastroenterología</i> , 2022, 37, 48-57.	0.1	0
461	Venous Thromboembolism in Admitted Patients with Inflammatory Bowel Disease: An Enterprise-Wide Experience of 86,000 Hospital Encounters. <i>Diseases of the Colon and Rectum</i> , 2022, Publish Ahead of Print, .	0.7	3
462	Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 62-69.	0.9	3
463	Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	1.9	5
464	Evaluation of Anti-Inflammatory and Antioxidant Effects of Chrysanthemum Stem and Leaf Extract on Zebrafish Inflammatory Bowel Disease Model. <i>Molecules</i> , 2022, 27, 2114.	1.7	16
465	Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. <i>Frontiers in Public Health</i> , 2022, 10, 851295.	1.3	10
466	Measurement of Serum IgG Anti-Integrin $\alpha 4$ Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1881.	1.0	13
467	Artificial Intelligence Program to Predict p53 Mutations in Ulcerative Colitis-Associated Cancer or Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1072-1080.	0.9	7
468	Evolving roles of magnifying endoscopy and endoscopic resection for neoplasia in inflammatory bowel diseases. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 646-653.	0.8	1

#	ARTICLE	IF	CITATIONS
469	Acute entire colitis and vein thrombosis after COVID-19 mRNA vaccination. <i>Digestive Endoscopy</i> , 2022, 34, 1069-1069.	1.3	1
470	Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2868-2875.e1.	2.4	9
471	Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. <i>Translational Research</i> , 2022, 246, 78-86.	2.2	1
472	Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid. <i>Nutrients</i> , 2022, 14, 1069.	1.7	21
473	New insights on the surgical management of ulcerative colitis in the 21st century. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 679-688.	3.7	7
474	Baccharis dracunculifolia DC Hydroalcoholic Extract Improves Intestinal and Hippocampal Inflammation and Decreases Behavioral Changes of Colitis Mice. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-14.	0.5	1
475	Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial. <i>EClinicalMedicine</i> , 2022, 45, 101332.	3.2	18
476	Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1826-1832.	0.9	21
477	ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment. <i>Materials Today Bio</i> , 2022, 14, 100246.	2.6	32
478	Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1569-1580.	1.9	8
479	Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn's disease patients. <i>Annals of Medicine</i> , 2022, 54, 886-892.	1.5	7
480	Traditional Chinese Medicine Alleviates Ulcerative Colitis via Modulating Gut Microbiota. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-6.	0.5	10
481	Qingchang decoction retention enema may induce clinical and mucosal remission in left-sided ulcerative colitis: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 3573-3578.	0.3	0
482	Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 51-61.	0.9	5
483	Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, 31.	0.9	21
484	Molecular mechanisms of Huanglian jiedu decoction on ulcerative colitis based on network pharmacology and molecular docking. <i>Scientific Reports</i> , 2022, 12, 5526.	1.6	8
485	Chinese herbal medicines in the treatment of ulcerative colitis: a review. <i>Chinese Medicine</i> , 2022, 17, 43.	1.6	16
486	Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 90-100.	2.3	5

#	ARTICLE	IF	CITATIONS
487	Berberine inhibits IFN- $\hat{3}$ signaling pathway in DSS-induced ulcerative colitis. Saudi Pharmaceutical Journal, 2022, 30, 764-778.	1.2	7
488	Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clinical Gastroenterology and Hepatology, 2023, 21, 2407-2409.e2.	2.4	7
489	Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. The Cochrane Library, 2022, 2022, CD007216.	1.5	3
490	Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1. Inflammatory Bowel Diseases, 2023, 29, 238-244.	0.9	5
491	Diet in Benign Colonic Disorders: A Narrative Review. Clinical Therapeutics, 2022, 44, 657-670.	1.1	5
492	Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners. Journal for Nurse Practitioners, 2022, 18, 438-445.	0.4	0
493	The Immunomodulatory Functions of Butyrate. Journal of Inflammation Research, 2021, Volume 14, 6025-6041.	1.6	105
494	Potential Biomarkers Associated with Differential Manifestations of Ulcerative Colitis (UC) in Uyghur and Han Population in China. Journal of Inflammation Research, 2021, Volume 14, 7431-7441.	1.6	2
495	Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis. BMJ Open, 2021, 11, e055182.	0.8	0
496	Heterogeneity in outcome assessment for inflammatory bowel disease in routine clinical practice: a mixed-methods study in a sample of English hospitals. BMJ Open, 2021, 11, e056413.	0.8	3
497	Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterology, 2021, 21, 494.	0.8	0
498	Artificial Neural Network Analysis-Based Immune-Related Signatures of Primary Non-Response to Infliximab in Patients With Ulcerative Colitis. Frontiers in Immunology, 2021, 12, 742080.	2.2	4
499	A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohn's & Colitis 360, 2022, 4, .	0.5	2
500	Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety) Tj ETQq1 1 0.784314 rgBT /Over	1.1	14
501	Implementing Collaborative Care Management of Behavioral Health for Patients with Inflammatory Bowel Disease. Inflammatory Intestinal Diseases, 2022, 7, 97-103.	0.8	2
502	Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. Digestive Diseases, 2022, 40, 553-564.	0.8	4
503	Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn's Disease. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	1.1	3
505	Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflammatory Bowel Diseases, 2022, 28, 1555-1564.	0.9	5

#	ARTICLE	IF	CITATIONS
506	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	0.6	6
507	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 265-272.	1.9	13
508	Part I: Inflammatory bowel disease. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 1514-1519.	0.5	0
509	Stopping Surveillance in Gastrointestinal Conditions: Thoughts on the Scope of the Problem and Potential Solutions. <i>Gastroenterology</i> , 2022, 163, 345-349.	0.6	2
510	Modern Metaproteomics: A Unique Tool to Characterize the Active Microbiome in Health and Diseases, and Pave the Road towards New Biomarkers—Example of Crohn's Disease and Ulcerative Colitis Flare-Ups. <i>Cells</i> , 2022, 11, 1340.	1.8	11
511	Enthesitis in Bowel-Associated Dermatitis-Arthritis Syndrome in an Ulcerative Colitis Patient. <i>Case Reports in Rheumatology</i> , 2022, 2022, 1-4.	0.2	1
512	Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1208-1209.	1.9	0
513	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	3
514	Editorial: response to tofacitinib is associated with high rates of long-term treatment persistence. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1222-1223.	1.9	0
515	Rapid development of accurate artificial intelligence scoring for colitis disease activity using applied data science techniques. <i>Endoscopy International Open</i> , 2022, 10, E539-E543.	0.9	3
516	A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, , .	1.4	1
523	Staging Considerations for the Ileal Pouch-Anal Anastomosis. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1531-1536.	0.9	0
524	Current Venous Thromboembolism Chemoprophylaxis Practices After Surgery for Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1296-1297.	0.9	1
525	Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis. <i>Histology and Histopathology</i> , 2020, 35, 1379-1389.	0.5	5
527	Efficacy of faecal microbiota transplantation on ulcerative colitis and its effect on gastrointestinal motility and immune function.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 14057-14066.	0.0	0
528	Description of the inflammatory bowel disease natural history in Tehran province, Iran: Mixed panel approaches.. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2021, 14, S66-S74.	0.6	0
529	Screening for gastrointestinal and pancreatic diseases. <i>Advances in Clinical Chemistry</i> , 2022, , 129-153.	1.8	1
531	Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210908.	1.4	0

#	ARTICLE	IF	CITATIONS
533	Effects of Pine Pollen Polysaccharides and Sulfated Polysaccharides on Ulcerative Colitis in Mice by Regulating Th17/Treg. SSRN Electronic Journal, 0, .	0.4	0
534	Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases. Current Medical Research and Opinion, 2022, 38, 1093-1101.	0.9	4
535	Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterology Clinics of North America, 2022, 51, 369-379.	1.0	2
536	Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis. World Journal of Gastroenterology, 2022, 28, 1705-1717.	1.4	6
537	Clinicopathologic features of undetected dysplasia found in total colectomy or proctocolectomy specimens of patients with inflammatory bowel disease. Histopathology, 2022, 81, 183-191.	1.6	7
538	An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opinion on Pharmacotherapy, 2022, 23, 893-904.	0.9	3
539	Increased Risk for Dementia in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Population-Based Studies. Frontiers in Neurology, 2022, 13, .	1.1	6
540	Musculoskeletal Ultrasound to Identify Subclinical Joint and Periarticular Involvement in Patients With Inflammatory Bowel Disease: A Systematic Literature Review. Frontiers in Medicine, 2022, 9, .	1.2	2
541	Antibiotics for the induction and maintenance of remission in ulcerative colitis. The Cochrane Library, 2022, 2022, CD013743.	1.5	8
542	Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet, The, 2022, 399, 2113-2128.	6.3	187
543	Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial. Frontiers in Psychiatry, 2022, 13, .	1.3	3
544	Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes. Current Medical Research and Opinion, 2022, 38, 1531-1541.	0.9	2
545	Prevalence and clinical features of patients with autoimmune pancreatitis and inflammatory bowel disease: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1474-1484.	1.4	2
546	Endoscopic ultrasonography in the evaluation of condition and prognosis of ulcerative colitis. World Journal of Clinical Cases, 2022, 10, 4818-4826.	0.3	1
547	Beneficial Effects of Celastrol on Immune Balance by Modulating Gut Microbiota in Experimental Ulcerative Colitis Mice. Genomics, Proteomics and Bioinformatics, 2022, 20, 288-303.	3.0	9
549	Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB). BMC Gastroenterology, 2022, 22, .	0.8	1
550	Intestinal Barrier Dysfunction in the Absence of Systemic Inflammation Fails to Exacerbate Motor Dysfunction and Brain Pathology in a Mouse Model of Parkinson's Disease. Frontiers in Neurology, 2022, 13, .	1.1	13
551	Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intestinal Research, 2023, 21, 61-87.	1.0	17

#	ARTICLE	IF	CITATIONS
552	Gut Microbiota and Metabolite Changes in Patients With Ulcerative Colitis and Clostridioides difficile Infection. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	10
553	Prevalence and factors associated with fatigue in patients with ulcerative colitis in China: a cross-sectional study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
554	Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. <i>Crohn's & Colitis</i> 360, 2022, 4, .	0.5	8
555	Prevention of eating disorders in specialty care. <i>Nutricion Hospitalaria</i> , 2022, , .	0.2	0
556	The role of PET imaging in inflammatory bowel diseases: state-of-the-art review. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	0.4	6
557	Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study. <i>British Journal of Dermatology</i> , 2022, 187, 692-703.	1.4	19
558	Regulation of the Intestinal Extra-Adrenal Steroidogenic Pathway Component LRH-1 by Glucocorticoids in Ulcerative Colitis. <i>Cells</i> , 2022, 11, 1905.	1.8	3
559	Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 570-578.	0.9	9
560	The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease. <i>Biomedicines</i> , 2022, 10, 1492.	1.4	18
561	Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial. <i>American Journal of Gastroenterology</i> , 2022, 117, 1508-1518.	0.2	3
562	Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2022, 16, 840-848.	1.4	7
563	Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2023, 68, 1006-1015.	1.1	9
564	Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	2
565	Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician. <i>Biologics: Targets and Therapy</i> , 0, Volume 16, 67-83.	3.0	0
566	Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2022, 163, 937-949.e2.	0.6	23
567	Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	15
568	Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 962-972.	3.7	5
569	The diagnosis and management of CMV colitis in IBD patients shows high practice variation: a national survey among gastroenterologists. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1321-1326.	0.6	6

#	ARTICLE	IF	CITATIONS
570	Increased Risk of Non-conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1825-1834.	0.6	7
571	Is the Risk for Venous Thromboembolism in East Asian Patients with Inflammatory Bowel Disease Comparable to That in Western Patients?. <i>Gut and Liver</i> , 2022, 16, 495-496.	1.4	0
573	Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	2
574	Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases. <i>World Journal of Gastroenterology</i> , 2022, 28, 2843-2853.	1.4	0
575	Inflammatory Bowel Disease Self-Management. <i>Gastroenterology Nursing</i> , 0, Publish Ahead of Print, .	0.2	0
576	Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1030-1043.	1.9	18
577	Aromatic-turmerone ameliorates DSS-induced ulcerative colitis via modulating gut microbiota in mice. <i>Inflammopharmacology</i> , 2022, 30, 1283-1294.	1.9	6
578	Curative effects of fucoidan on acetic acid induced ulcerative colitis in rats via modulating aryl hydrocarbon receptor and phosphodiesterase-4. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, .	1.2	12
579	Update of the PANCCO clinical practice guidelines for the treatment of ulcerative colitis in the adult population. <i>Revista De GastroenterologAa De MÃ©xico (English Edition)</i> , 2022, , .	0.1	1
580	Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 737-752.	1.4	8
581	<i>Clostridium difficile</i> Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	1
582	Update on gut microbiota in gastrointestinal diseases. <i>World Journal of Clinical Cases</i> , 2022, 10, 7653-7664.	0.3	4
584	Dyslipidaemia Is Associated with Severe Disease Activity and Poor Prognosis in Ulcerative Colitis: A Retrospective Cohort Study in China. <i>Nutrients</i> , 2022, 14, 3040.	1.7	7
585	Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 675-683.	0.9	4
586	Editorial: measuring disease severity in inflammatory bowel diseaseâ€”the whole is greater than the sum of its parts. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 744-745.	1.9	1
587	Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-Î±. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 895-905.	0.7	5
588	Safety and tolerability of spesolimab in patients with ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 141-152.	1.0	14
589	An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis. <i>Medicine (United States)</i> , 2022, 101, e29790.	0.4	0

#	ARTICLE	IF	CITATIONS
590	Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-10.	0.5	3
591	Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study. Journal of Crohn's and Colitis, 2023, 17, 211-220.	0.6	4
592	Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. Current Oncology, 2022, 29, 6091-6114.	0.9	32
593	Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in Colonic Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 0, , .	0.1	2
594	Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2022, 80, 60-65.	0.2	1
595	(Re)Appraising Remission in Ulcerative Colitis. Inflammatory Bowel Diseases, 0, , .	0.9	0
596	The Feasibility, Safety, and Long-term Outcomes of Endoscopic Submucosal Dissection for Colorectal Neoplasia in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2023, 57, 721-730.	1.1	1
597	Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis in clinical practice. JGH Open, 2022, 6, 612-620.	0.7	3
598	Ozanimod: A Review in Ulcerative Colitis. Drugs, 2022, 82, 1303-1313.	4.9	12
599	Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis. Journal of Translational Medicine, 2022, 20, .	1.8	12
600	Clinical procedures used to diagnose inflammatory bowel disease: real-world evidence from a Danish nationwide population-based study. BMJ Open Gastroenterology, 2022, 9, e000958.	1.1	2
601	Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 3637-3648.	1.2	4
602	Development of microparticles for oral administration of <i>Periplaneta americana</i> extract to treat ulcerative colitis. Drug Delivery, 2022, 29, 2723-2733.	2.5	3
603	Evidence-based pathogenesis and treatment of ulcerative colitis: A causal role for colonic epithelial hydrogen peroxide. World Journal of Gastroenterology, 2022, 28, 4263-4298.	1.4	6
604	Colorectal cancer risk of flat low-grade dysplasia in inflammatory bowel disease: a systematic review and proportion meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2023, 37, 48-61.	1.3	2
605	Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology, 2022, 163, 1555-1568.	0.6	18
606	Efficacy of integrated traditional Chinese and Western medicine on ulcerative colitis: A systematic review and meta-analysis. Pharmacological Research Modern Chinese Medicine, 2022, 4, 100145.	0.5	2
608	Efficacy and safety of ozanimod for ulcerative colitis (review). Koloproktologia, 2022, 21, 119-129.	0.1	0

#	ARTICLE	IF	CITATIONS
609	AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2023, 77, 659-702.	3.6	68
610	Progress in Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection. <i>Advances in Clinical Medicine</i> , 2022, 12, 7627-7633.	0.0	0
611	Blue Light Irradiation Alleviated Dextran Sulfate Sodium-Induced Colitis, Mediated by Baml1 Pathway in Macrophages. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
612	Pyoderma gangrenosum with acute severe ulcerative colitis successfully treated with oral cyclosporine: a case report. <i>Y Hoc Thanh Pho Ho Chi Minh</i> , 2022, 6, S44-S49.	0.1	0
613	Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review. <i>Cancers</i> , 2022, 14, 4254.	1.7	10
614	Esculentoside A Alleviates Intestinal Dysmotility in Ulcerative Colitis by Regulating H2S/CSE and NO/nNOS Systems. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-9.	0.5	2
615	5-Aminosalicylic acid ameliorates dextran sulfate sodium-induced colitis in mice by modulating gut microbiota and bile acid metabolism. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	31
616	Identifying surrogate markers in real-world comparative effectiveness research. <i>Statistics in Medicine</i> , 2022, 41, 5290-5304.	0.8	1
617	Clinical outcomes amongst elderly patients with inflammatory bowel disease. <i>Internal Medicine Journal</i> , 0, , .	0.5	1
618	Osteonecrosis in Inflammatory Bowel Disease: Clinical Features, Risk Factor Analysis, and Outcomes. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	0
619	An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 277-288.	0.6	2
620	Cancer in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 649-666.	1.0	20
621	Future of Endoscopy in Inflammatory Bowel Diseases (IBDs). <i>Cureus</i> , 2022, , .	0.2	0
622	Estrategias actuales en el diagnóstico y seguimiento de las enfermedades inflamatorias intestinales. <i>Acta Gastroenterologica Latinoamericana</i> , 2022, 52, 306-321.	0.0	0
623	An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5439-5443.	1.1	2
624	Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis. <i>Meditsinskiy Sovet</i> , 2022, , 90-97.	0.1	1
625	Risk factors for colorectal cancer in IBD patients. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2022, , 140-146.	0.1	1
626	Endoscopic Management of Colitis-Associated Neoplasia. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2022, 32, 863-873.	0.6	0

#	ARTICLE	IF	CITATIONS
627	Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn's disease. <i>Journal of Gastroenterology</i> , 2023, 58, 14-24.	2.3	9
628	Methodology and algorithms for the formation of prognostic decisions in gastroenterology on the example of ulcerative colitis. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2022, , 46-52.	0.1	0
629	Development and Course of Inflammatory Bowel Disease-Associated Intestinal Cancer. , 2022, , 23-31.		0
630	Protective Effect of Dietary Polysaccharides from Yellow Passion Fruit Peel on DSS-Induced Colitis in Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-15.	1.9	7
631	Prophylaxis for <i>Pneumocystis jirovecii</i> pneumonia in patients with inflammatory bowel disease: A systematic review. <i>Pharmacotherapy</i> , 2022, 42, 858-867.	1.2	5
632	Infliximab Induction Strategies in Corticosteroid-Refractory Acute Severe Ulcerative Colitis: A Case Series and Literature Review. <i>GE Portuguese Journal of Gastroenterology</i> , 0, , 1-8.	0.3	0
633	Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn's Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 535-552.	0.6	23
634	Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	0
635	Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease. <i>Current Medical Research and Opinion</i> , 2023, 39, 63-69.	0.9	0
636	Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records. <i>Uppsala Journal of Medical Sciences</i> , 0, 127, .	0.4	3
637	Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e30590.	0.4	5
638	Gene panel testing detects important genetic alterations in ulcerative colitis-associated colorectal neoplasia. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
639	Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. <i>Digestive Diseases and Sciences</i> , 2023, 68, 1464-1472.	1.1	6
640	Diagnosis and Monitoring of Ulcerative Colitis. <i>Clinics in Colon and Rectal Surgery</i> , 2022, 35, 421-427.	0.5	1
641	Mesenchymal stem cells: A novel treatment option for primary sclerosing cholangitis. <i>Cell Biology International</i> , 2023, 47, 467-479.	1.4	1
642	Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. <i>Current Gastroenterology Reports</i> , 0, , .	1.1	2
643	The CGRP/macrophage axis signal facilitates inflammation recovery in the intestine. <i>Clinical Immunology</i> , 2022, 245, 109154.	1.4	3
644	Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study. <i>Pharmaceutics</i> , 2022, 14, 2449.	2.0	1

#	ARTICLE	IF	CITATIONS
646	Interobserver agreement of the modified Paris classification and histology prediction of colorectal lesions in patients with inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2023, 97, 790-798.e2.	0.5	2
647	Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 27-41.	0.9	13
649	Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, .	0.9	3
650	Micronutrient deficiency among patients with ulcerative colitis. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, .	0.3	1
651	Recent advances in surveillance colonoscopy for dysplasia in inflammatory bowel disease. <i>Clinical Endoscopy</i> , 2022, 55, 726-735.	0.6	4
652	Single-cell RNA-sequencing combined with bulk RNA-sequencing analysis of peripheral blood reveals the characteristics and key immune cell genes of ulcerative colitis. <i>World Journal of Clinical Cases</i> , 0, 10, 12116-12135.	0.3	1
653	Medication use among patients with Crohn's disease or ulcerative colitis before and after the initiation of advanced therapy. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
654	Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211406.	1.4	3
655	ACSF2-mediated ferroptosis is involved in ulcerative colitis. <i>Life Sciences</i> , 2023, 313, 121272.	2.0	10
656	Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	7
657	Elective and Emergent Surgery in the Ulcerative Colitis Patient. <i>Clinics in Colon and Rectal Surgery</i> , 0, , .	0.5	0
658	Predictive models for endoscopic disease activity in patients with ulcerative colitis: Practical machine learning-based modeling and interpretation. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
659	Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. <i>Clinical Pharmacokinetics</i> , 2023, 62, 101-112.	1.6	4
660	Inflammatory Bowel Disease Patients' Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study. <i>Digestive Diseases</i> , 2023, 41, 412-421.	0.8	2
661	Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008-2017: a multicenter retrospective study in China. <i>Intestinal Research</i> , 2023, 21, 235-243.	1.0	4
662	Performing colonoscopy before steroid induction is associated with shorter steroid use in patients with ulcerative colitis. <i>Intestinal Research</i> , 0, , .	1.0	0
663	Controlling in and out - the future of interfering with immune cell trafficking in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 155-167.	1.3	0
664	Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis. <i>International Journal of Clinical Pharmacy</i> , 2023, 45, 330-341.	1.0	1

#	ARTICLE	IF	CITATIONS
665	Blue light irradiation alleviated dextran sulfate sodium-induced colitis mediated by the Bmal1 pathway in macrophages. <i>Journal of Photochemistry and Photobiology</i> , 2022, 12, 100156.	1.1	0
666	Exploring Disease Remission and Bowel Urgency Severity Among Adults with Moderate to Severe Ulcerative Colitis: A Qualitative Study. <i>Patient Related Outcome Measures</i> , 0, Volume 13, 287-300.	0.7	4
667	Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission. <i>Crohn's & Colitis 360</i> , 2023, 5, .	0.5	8
668	Integrated bioinformatics to identify potential key biomarkers for COVID-19-related chronic urticaria. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
670	Medical Treatment Options for Ulcerative Colitis. <i>Clinics in Colon and Rectal Surgery</i> , 2022, 35, 428-436.	0.5	2
672	Increased Proportion of Colorectal Cancer in Patients With Ulcerative Colitis Undergoing Surgery in the Netherlands. <i>American Journal of Gastroenterology</i> , 2023, Publish Ahead of Print, .	0.2	0
674	Wumei Wan attenuates angiogenesis and inflammation by modulating RAGE signaling pathway in IBD: Network pharmacology analysis and experimental evidence. <i>Phytomedicine</i> , 2023, 111, 154658.	2.3	17
675	Ulcerative colitis complicated with Fournier's gangrene: A case report. , 2023, 3, 1-7.		0
676	Metagenomic analysis of Tongxie Yaofang therapy for rat models of ulcerative colitis with liver depression and spleen deficiency syndrome. <i>International Journal of Transgender Health</i> , 2023, 16, 1-12.	1.1	1
677	Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland. <i>Medical Science Monitor</i> , 0, 29, .	0.5	0
678	S818 An Insight into the Patient's Perspective of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts: Key Triggers and Symptoms of Flares. <i>American Journal of Gastroenterology</i> , 2022, 117, e588-e589.	0.2	0
679	A Rare Case of Pseudomembrane-Associated Ulcerative Colitis. <i>Cureus</i> , 2022, , .	0.2	0
680	Cayratia japonica Prevents Ulcerative Colitis by Promoting M2 Macrophage Polarization through Blocking the TLR4/MAPK/NF- κ B Pathway. <i>Mediators of Inflammation</i> , 2022, 2022, 1-20.	1.4	5
681	Network meta-analysis and cost-effectiveness analysis of infliximab, cyclosporine and tacrolimus for ulcerative colitis. <i>Medicine (United States)</i> , 2022, 101, e31850.	0.4	0
682	Sargassum horneri Extract Ameliorates DSS-Induced Colitis through Modulation of mTOR Axis and Intestinal Microbiota. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 1742.	1.3	0
683	Identification of gene signatures associated with ulcerative colitis and the association with immune infiltrates in colon cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
684	Inflammatory Bowel Disease and Colorectal Cancer. <i>Digestive Disease Interventions</i> , 0, , .	0.3	0
685	Cepharanthine Alleviates DSS-Induced Ulcerative Colitis via Regulating Aconitate Decarboxylase 1 Expression and Macrophage Infiltration. <i>Molecules</i> , 2023, 28, 1060.	1.7	3

#	ARTICLE	IF	CITATIONS
686	Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	2
687	Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. <i>Cancers</i> , 2023, 15, 871.	1.7	10
688	Clinical Diagnosis and Pharmaceutical Management of Inflammatory Bowel Disease. <i>Medical Research Archives</i> , 2023, 11, .	0.1	2
689	Colitis-Associated Cancers. , 2023, , 773-788.		0
690	Conventional treatment and new drugs. , 2023, , 47-69.		0
691	Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2023, 68, 897-901.	1.1	1
692	Câ€reactive protein/albumin ratio and <scp>IL</scp>â€6 are associated with disease activity in patients with ulcerative colitis. <i>Journal of Clinical Laboratory Analysis</i> , 2023, 37, .	0.9	3
693	Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	0
694	Colonic Dilatation Complicating Acute Severe Ulcerative Colitis Managed Successfully with Accelerated Infliximab Dosing. <i>Case Reports in Gastroenterology</i> , 2023, 17, 82-88.	0.3	0
695	Risk of venous thromboembolism with a central venous catheter in hospitalized Japanese patients with inflammatory bowel disease: a propensity score-matched cohort study. <i>Intestinal Research</i> , 2023, 21, 318-327.	1.0	0
696	Neutrophil Membrane-Coated Mesoporous Silica Nanoparticles Loaded with Hydrocortisone Alleviate DSS-Induced Colitis in Mice. <i>ACS Applied Nano Materials</i> , 2023, 6, 2403-2412.	2.4	0
697	Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482311512.	1.4	2
698	A Joint Effort: Improving the Identification of Spondyloarthritis in Patients With Inflammatory Bowel Disease. <i>Journal of Rheumatology</i> , 2023, 50, 855-856.	1.0	0
699	The Role of Artificial Intelligence in Monitoring Inflammatory Bowel Diseaseâ€”The Future Is Now. <i>Diagnostics</i> , 2023, 13, 735.	1.3	1
701	Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	1
702	AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. <i>Gastroenterology</i> , 2023, 164, 344-372.	0.6	19
703	Risk prediction model based on blood biomarkers for predicting moderate to severe endoscopic activity in patients with ulcerative colitis. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
704	Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 15, 125-138.	0.7	1

#	ARTICLE	IF	CITATIONS
705	Rectal Cancer and Radiation in Colitis. <i>Clinics in Colon and Rectal Surgery</i> , 2024, 37, 030-036.	0.5	0
706	Discovery, Preliminary Structure-Activity Relationship, and Evaluation of Oleanane-Type Saponins from <i>Pulsatilla chinensis</i> for the Treatment of Ulcerative Colitis. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3635-3647.	2.9	2
707	The role of capsule endoscopy in diagnosis and clinical management of inflammatory bowel disease. , 2023, , 69-90.		0
708	Managing Risk of Dysplasia and Colorectal Cancer in Inflammatory Bowel Disease. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2023, 25, 372-384.	0.4	0
709	Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports. <i>Journal of Medical Case Reports</i> , 2023, 17, .	0.4	2
710	Automated Clinical Pathway Utilizing Custom Risk Stratification Identifies Substantial Rates of Overdue Follow-up Among Patients With Inflammatory Bowel Disease and Facilitates Population Health Interventions. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	0
711	Predictors of steroid dependence and resistance in patients with ulcerative colitis. <i>Koloproktologia</i> , 2023, 22, 99-107.	0.1	0
712	Low risk of new dysplastic lesions in an inflammatory bowel disease population study with dye-chromoendoscopy. <i>Endoscopy International Open</i> , 0, , .	0.9	0
713	Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. <i>Clinical and Translational Gastroenterology</i> , 2023, 14, e00578.	1.3	3
714	Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	2
715	Identifying, Understanding, and Managing Fecal Urgency in Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1403-1413.e27.	2.4	5
716	Testing of Coding Algorithms for Inflammatory Bowel Disease Identification, as Indication for Use of Biological Drugs, Using a Claims Database from Southern Italy. <i>Clinical Epidemiology</i> , 0, Volume 15, 309-321.	1.5	2
718	Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib. <i>Medicina (Lithuania)</i> , 2023, 59, 542.	0.8	5
720	Interventional Procedures for Inflammatory Bowel Disease. , 2023, , 273-285.		0
721	Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. <i>Przegląd Gastroenterologiczny</i> , 2023, 18, 1-42.	0.3	1
722	Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 1207-1216.	0.6	1
723	Haze, Gray, and Endoscopy Underway. , 2023, , 315-367.		0
724	Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2024, 30, 64-77.	0.9	2

#	ARTICLE	IF	CITATIONS
725	Behavioral abnormalities in C57BL/6 mice with chronic ulcerative colitis induced by DSS. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	4
726	Multimomics-empowered Deep Phenotyping of Ulcerative Colitis Identifies Biomarker Signatures Reporting Functional Remission States. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 1514-1527.	0.6	4
727	Current Screening and Management Strategies for Dysplasia in IBD. <i>Current Treatment Options in Gastroenterology</i> , 0, , .	0.3	0
728	Study on the anti-inflammatory effect of stachyose by inhibiting TLR4 / $\text{NF-}\kappa\text{B}$ signalling pathway in vitro and in vivo. <i>Clinical and Experimental Pharmacology and Physiology</i> , 0, , .	0.9	0
729	Risk of Attempted Suicide Among Patients with Inflammatory Bowel Disease: A Nationwide Longitudinal Follow-Up Study. <i>Diseases of the Colon and Rectum</i> , 0, Publish Ahead of Print, .	0.7	1
730	Vedolizumab for the Treatment of Chronic Pouchitis. <i>New England Journal of Medicine</i> , 2023, 388, 1191-1200.	13.9	18
731	Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial. <i>Clinical Drug Investigation</i> , 2023, 43, 277-288.	1.1	3
732	Tofacitinib experience in patients with enteropathic arthritis. <i>Immunotherapy</i> , 0, , .	1.0	0
733	DNA content abnormality frequently develops in the right/proximal colon in patients with primary sclerosing cholangitis and inflammatory bowel disease and is highly predictive of subsequent detection of dysplasia. <i>Histopathology</i> , 0, , .	1.6	0
734	Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need from the CorEvitas Inflammatory Bowel Disease Registry. , 2023, , .		0
735	Protective Effect of Qingchang Wenzhong Decoction on Colitis and Colitis-Related Carcinogenesis by Regulating Inflammation and Intestinal Fibrosis. <i>Journal of Inflammation Research</i> , 0, Volume 16, 1479-1495.	1.6	2
736	Management of Dysplasia in Inflammatory Bowel Disease. <i>Clinics in Colon and Rectal Surgery</i> , 2024, 37, 018-021.	0.5	0
737	Role and Impact of a Clinical Pharmacy Team at an Inflammatory Bowel Disease Center. <i>Crohn's & Colitis</i> 360, 2023, 5, .	0.5	1
738	Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease. <i>Annals of Medicine</i> , 2023, 55, .	1.5	1
749	Fulminant/Toxic Colitis. , 2023, , 1207-1225.		0
862	Complicated Inflammatory Bowel Disease and Colonic Non-diverticular Emergencies. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2023, , 87-101.	0.1	0
894	Colonic Dysplasia in Patients with Ulcerative Colitis: Endoscopic or Surgical Management?. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2023, , 113-125.	0.0	0
913	The Role of the Microbiome in Inflammatory Bowel Disease. , 2023, , 117-127.		0

#	ARTICLE	IF	CITATIONS
914	Case report: Successful treatment of ulcerative colitis-related post-colectomy enteritis refractory to multiple therapies with ustekinumab. <i>Frontiers in Immunology</i> , 0, 15, .	2.2	0
922	DNA flow cytometry for detection of genomic instability as a cancer precursor in the gastrointestinal tract. <i>Methods in Cell Biology</i> , 2024, , .	0.5	0